Related Experiment Video
Updated: May 10, 2025
Author Spotlight: Simulating Pediatric Cardiac Surgery Using a Neonatal Piglet Model
Published on: May 26, 2023
Diluted Regional Citrate Anticoagulation for Continuous Renal Replacement Therapy in Pediatric Patients: A Systematic
Sidharth Kumar Sethi1, Ashita Tolwani2, Omer S Ashruf3
1Pediatric Nephrology, Kidney Institute, Medanta, The Medicity Hospital, Gurgaon, India.
Insights
Regional citrate anticoagulation (RCA) effectively reduces clotting and prolongs circuit life in pediatric continuous renal replacement therapy (CRRT). A modified protocol using diluted citrate offers a safer approach, minimizing metabolic and electrolyte disturbances in critically ill children.
Area of Science:
- Pediatric Nephrology
- Critical Care Medicine
- Biomedical Engineering
Background:
- Continuous renal replacement therapy (CRRT) is crucial for critically ill pediatric patients with acute kidney injury (AKI).
- Anticoagulation choice in CRRT is critical to prevent circuit clotting and bleeding complications.
- Regional citrate anticoagulation (RCA) is favored in pediatrics due to its safety profile, especially in bleeding-prone patients.
Purpose of the Study:
- To evaluate the efficacy and safety of regional citrate anticoagulation (RCA) in pediatric continuous renal replacement therapy (CRRT).
- To compare RCA with other anticoagulation methods, particularly heparin, in pediatric CRRT.
- To introduce and assess a modified pediatric citrate protocol designed to mitigate adverse events.
Main Methods:
- A systematic literature review was performed using PRISMA guidelines across PubMed, Google Scholar, and Cochrane databases.
- Included studies focused on neonates and pediatric patients undergoing CRRT with RCA, reporting citrate concentration and safety/efficacy outcomes.
- Data extraction covered study characteristics, citrate concentration, circuit lifespan, metabolic/electrolyte disturbances, and adverse effects.
Main Results:
- Regional citrate anticoagulation (RCA) demonstrated fewer clotting events and longer circuit lifespan compared to heparin.
- Identified complications included metabolic alkalosis, hypocalcemia, and hypernatremia.
- A single-center experience with a dilute citrate protocol in 16 pediatric patients showed reduced clotting and prolonged circuit life.
Conclusions:
- Regional citrate anticoagulation (RCA) is effective for prolonging circuit life and reducing clotting in pediatric CRRT.
- A modified pediatric citrate protocol using diluted citrate offers a potentially safer alternative, reducing metabolic and electrolyte disturbances.
- Close monitoring of calcium and electrolyte levels is essential for safe RCA implementation in pediatric CRRT.
Introduction:
Continuous renal replacement therapy (CRRT) is increasingly used in critical pediatric patients with acute kidney injury (AKI). The choice of anticoagulant is vital to minimize circuit clotting and bleeding complications. Regional citrate anticoagulation (RCA) is preferred for its safety profile, particularly in critically ill pediatric patients who are susceptible to bleeding.
Methods:
A comprehensive literature search was conducted using PubMed, Google Scholar, and Cochrane databases following PRISMA guidelines. Keywords included "diluted citrate," "regional citrate anticoagulation," "continuous renal replacement therapy," "pediatrics," and "adverse effects." Studies were included if they involved neonates and pediatric patients, reported citrate concentration, and safety and efficacy outcomes of RCA in CRRT. Data were extracted on study characteristics, citrate concentration, circuit lifespan, metabolic and electrolyte disturbances, and other adverse effects.
Results:
A total of 16 studies met the inclusion criteria. RCA was associated with fewer clotting events and a longer median circuit life compared to heparin. However, complications such as metabolic alkalosis, hypocalcemia, and hypernatremia were noted. In our single-center experience, dilute citrate anticoagulation was used in 16 pediatric patients undergoing CRRT, showing promising results with reduced clotting and prolonged circuit life. The modified pediatric citrate protocol presented aims to address complications by using a diluted citrate solution.
Conclusions:
RCA is effective in prolonging circuit life and reducing clotting in pediatric CRRT. The modified pediatric citrate protocol presents a safer alternative by reducing the risk of metabolic and electrolyte disturbances. Ongoing monitoring of calcium and electrolyte levels is essential to mitigate potential complications. This protocol may standardize RCA use in pediatric CRRT, improving safety and outcomes for critically ill children with AKI.
Related Concept Videos
01:27Parentral Nutrition: Centeral and Peripheral Parental Nutrition
PN can be administered through two primary routes:
1. Central Parenteral Nutrition (CPN):
CPN involves delivering a high concentration of nutrients through a large vein. This is typically achieved using a Peripherally Inserted Central Catheter (PICC) or,...
01:30Anticoagulant Drugs: Low-Molecular-Weight Heparins